Literature DB >> 20009966

Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases.

Guadalupe G Marin1, Mario H Cardiel, Horacio Cornejo, Martha E Viveros.   

Abstract

Antinuclear antibodies (ANA) are frequently found in healthy populations. To define the prevalence, pattern, and titer of ANA in different groups of the healthy Mexican population, we studied 304 individuals, classified into 3 groups: 104 blood donors, 100 hospital personnel working at The State General Hospital, which included doctors, laboratory technicians, and nurses; and 100 relatives of patient diagnosed either with systemic lupus erythematosus or rheumatoid arthritis, all of them apparently healthy at the time of study. We determined ANA using immunofluorescence microscopy performed on HEp-2 cells. Fluorescence was detected in 165 serum samples (54.3%). The most frequent pattern was the speckled (50.3%). The most frequent dilution was 1:40 (35.4%), followed by 1:80 (13.4%), 1:160 (3.2%), and 1:320 (1.3%).Regarding the results by study group, we found a trend toward higher ANA levels in group 2 (hospital personnel), compared with group 1 (blood donors) and group 3 (relatives of patients), a trend also reflected by the increasing frequency of serum titers of 1:80 and higher (P = 0.074). According to occupation, medical doctors showed a higher incidence of speckled pattern when compared with other occupations (P = 0.022). Medical doctors (n = 75) showed also higher titers of this particular pattern (P = 0.03). In group 3, relatives of patients with systemic lupus erythematosus showed the speckled pattern more frequently than relatives of patients with rheumatoid arthritis, in low titers (P = 0.017). We suggest that ANA tests showing speckled pattern should be at a 1:160 titer or higher to be considered positive; other patterns such as homogeneous, peripheral, or centromeric might be considered positive even at low titers (</=1:40) although this needs investigation.ANA should generally not be tested without clinical indication. Positive ANA finding in the absence of physical signs and symptoms has limited diagnostic utility and should always be interpreted by a rheumatologist, in the context of clinical symptoms and results of laboratory tests for specific autoantibodies. Populations such as doctors and relatives of patients with autoimmune disease tend to presents increased ANA titers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20009966     DOI: 10.1097/RHU.0b013e3181bb971b

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  25 in total

1.  The autoreactivity of B cells in hereditary angioedema due to C1 inhibitor deficiency.

Authors:  A Kessel; R Peri; R Perricone; M D Guarino; Z Vadasz; R Novak; T Haj; S Kivity; E Toubi
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

2.  Frequency and specificity of antibodies against nuclear and cytoplasmic antigens in healthy individuals by classic and new methods.

Authors:  E Giannouli; D Chatzidimitriou; S Gerou; E Gavriilaki; L Settas; E Diza
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980

3.  Evaluation of the reactivity of sera from patients with systemic lupus erythematosus against the human MCP1.

Authors:  Elsa Bronze-da-Rocha; Ana Nóvoa; Natércia Teixeira; Carlos Silva Vasconcelos; Conceição Cerveira; João Castro e Melo; Manuel Cirne Carvalho
Journal:  J Clin Immunol       Date:  2012-02-29       Impact factor: 8.317

4.  Nuclear fluorescence serum reactivity on monkey oesophagus: a new antibody for the follow-up of coeliac disease?

Authors:  A Picarelli; L Sabbatella; M Di Tola; M Silano; A Nicolussi; S D'Inzeo; A Coppa
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

5.  Determination of anti-nuclear antibody seroprevalence in adult age groups in trabzon province.

Authors:  Neşe Kaklıkkaya; Altan Akıneden; Murat Topbaş; Faruk Aydın
Journal:  Balkan Med J       Date:  2013-09       Impact factor: 2.021

6.  Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease.

Authors:  M Frodlund; J Wetterö; C Dahle; Ö Dahlström; T Skogh; J Rönnelid; C Sjöwall
Journal:  Clin Exp Immunol       Date:  2019-12-19       Impact factor: 4.330

Review 7.  Autoantibodies and SLE: the threshold for disease.

Authors:  Nancy J Olsen; David R Karp
Journal:  Nat Rev Rheumatol       Date:  2013-12-03       Impact factor: 20.543

Review 8.  Cutaneous lupus erythematosus: diagnosis and treatment.

Authors:  L G Okon; V P Werth
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-06       Impact factor: 4.098

9.  Excess female siblings and male fetal loss in families with systemic lupus erythematosus.

Authors:  Rachna Aggarwal; Andrea L Sestak; Eliza F Chakravarty; John B Harley; R Hal Scofield
Journal:  J Rheumatol       Date:  2013-02-01       Impact factor: 4.666

Review 10.  Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Nat Rev Rheumatol       Date:  2013-10-08       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.